Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer

• DOI: 10.1136/jitc-2022-006624
• Publication Date: 2023-06-09T14:02:11Z
• Authors: Mary L Disis; Sarah F Adams; Jyoti Bajpai; Marcus O Butler; Tyler Curiel; Shelley A Dodt; Laura Doherty; Leisha A Emens; Claire F Friedman; Margaret Gatti-Mays; Melissa A Geller; Amir Jazaeri; Veena S John; Katherine C Kurnit; John B Liao; Haider Mahdi; Anne Mills; Emese Zsiros; Kunle Odunsi
• Keywords: Guideline; Clinical Practice

Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) been approved by the US Food and Drug Administration for of cervical cancer endometrial cancer, offering durable responses some patients. In addition, many immunotherapy strategies are under investigation earlier stages disease or in other cancers, such as ovarian rare tumors. While integration ICIs into standard care has improved outcomes patients, their use requires a nuanced understanding biomarker testing, selection, patient response evaluation surveillance, quality life considerations, among topics. To address this need guidance, Society Immunotherapy Cancer (SITC) convened multidisciplinary panel experts to develop clinical practice guideline. The Expert Panel drew on published literature well own experience evidence- consensus-based recommendations provide guidance professionals treating patients with cancer.